Lactic acid - Stayble Therapeutics
Alternative Names: STA 363Latest Information Update: 05 Feb 2025
At a glance
- Originator Stayble Therapeutics
- Class Alkalinising agents; Analgesics; Hydroxy acids; Lactates; Small molecules
- Mechanism of Action Inflammation mediator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Intervertebral disc degeneration; Intervertebral disc displacement
Highest Development Phases
- Phase II Back pain
- Phase I/II Intervertebral disc displacement
Most Recent Events
- 22 Jan 2025 Efficacy data from a phase Ib/II trial in Intervertebral disc displacement released by Stayble Therapeutics
- 26 Dec 2024 9432941: No updates (transaction advisor support info)
- 30 Sep 2024 Stayble Therapeutics has patent protection for lactic acid for Back pain from herniated discs in South Africa